Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer

Open access
Galsky, Matthew D., Pal, Sumanta K., Chowdhury, Simon, Harshman, Lauren C., Crabb, Simon J., Wong, Yu‐Ning, Yu, Evan Y., Powles, Thomas, Moshier, Erin L., Ladoire, Sylvain, Hussain, Syed A., Agarwal, Neeraj, Vaishampayan, Ulka N., Recine, Federica, Berthold, Dominik, Necchi, Andrea, Theodore, Christine, Milowsky, Matthew I., Bellmunt, Joaquim, Rosenberg, Jonathan E., for the Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators · 2015 · Cancer

Abstract

BACKGROUND: Gemcitabine plus cisplatin (GC) has been adopted as a neoadjuvant regimen for muscle‐invasive bladder cancer despite the lack of Level I evidence in this setting. METHODS: Data were collected using an electronic data‐capture platform from 28 international centers. Eligible patients had clinical T‐classification 2 (cT2) through cT4aN0M0 urothelial cancer of the bladder and received neoadjuvant GC or methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) before undergoing cystectomy. Logistic regression was used to compute propensity scores as the predicted probabilities of patients being assigned to MVAC versus GC given their baseline characteristics. These propensity scores were then included in a new logistic regression model to estimate an adjusted odds ratio comparing the odds of attaining a pathologic complete response (pCR) between patients who received MVAC and those who received GC. RESULTS: In total, 212 patients (146 patients in the GC cohort and 66 patients in the MVAC cohort) met criteria for inclusion in the analysis. The majority of patients in the MVAC cohort (77%) received dose‐dense MVAC. The median age of patients was 63 years, they were predominantly men (74%), and they received a median of 3 cycles of neoadjuvant chemotherapy. The pCR rate was 29% in the MVAC cohort and 31% in the GC cohort. There was no significant difference in the pCR rate when adjusted for propensity scores between the 2 regimens (odds ratio, 0.91; 95% confidence interval, 0.48‐1.72; P = .77). In an exploratory analysis evaluating survival, the hazard ratio comparing hazard rates for MVAC versus GC adjusted for propensity scores was not statistically significant (hazard ratio, 0.78; 95% confidence interval, 0.40‐1.54; P = .48). CONCLUSIONS: Patients who received neoadjuvant GC and MVAC achieved comparable pCR rates in the current analysis, providing evidence to support what has become routine practice. Cancer 2015;121:2586–2593. © 2015 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.29387

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 190

Metadata

Authors
Galsky, M. D., Pal, S. K., Chowdhury, S., Harshman, L. C., Crabb, S. J., Wong, Y., Yu, E. Y., Powles, T., Moshier, E. L., Ladoire, S., Hussain, S. A., Agarwal, N., Vaishampayan, U. N., Recine, F., Berthold, D., Necchi, A., Theodore, C., Milowsky, M. I., Bellmunt, J., Rosenberg, J. E., & for the Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators
Venue
Cancer
Publisher
Wiley
Published
2015-04-14
Volume
121
Issue
15
Pages
2586-2593
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1845099892
Cited by
190
References
1
FWCI
22.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer. https://app.cochat.ai/papers/10.1002/cncr.29387
The paper
Galsky, M. D., Pal, S. K., Chowdhury, S., Harshman, L. C., Crabb, S. J., Wong, Y., Yu, E. Y., Powles, T., Moshier, E. L., Ladoire, S., Hussain, S. A., Agarwal, N., Vaishampayan, U. N., Recine, F., Berthold, D., Necchi, A., Theodore, C., Milowsky, M. I., Bellmunt, J., . . . for the Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. (2015). Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer. Cancer. https://doi.org/10.1002/cncr.29387

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.